SOPHIA Phase III study of Margenza announces final OS data in HER2-positive breast cancer patients – MacroGenics
MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase III study of Margenza (margetuximab-cmkb) in adult patients with metastatic HER2-positive breast cancer. The final OS… read more.
